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Dissections
Tolenaar JL, van Keulen JW, Trimarchi S, et al. Ann Thorac Surg
2013;96:39-42.
Conclusions: The number of entry tears detected on the ﬁrst
computed tomography angiography (CTA) study following acute type B
aortic dissection is a signiﬁcant predictor of subsequent aortic growth.
Summary: Patients with uncomplicated acute type B aortic dissection
treated conservatively by antihypertensive treatment have in-hospital mor-
tality rates between 1% and 10%. Favorable initial outcomes, however, are
mitigated by medium-term and long-term problems related to the aorta,
such as aneurysm growth and rupture. These delayed problems result in sur-
vival rates of 56% to 92% at 1 year and 48% to 82% at 5 years (Tsai TT et al,
N Engl J Med 2007;357:349-59). It is thought that impaired outﬂow of the
false lumen or increased inﬂow to the false lumen can lead to an increase in
mean and diastolic pressure in the false lumen. Acutely, this may lead to true
lumen collapse and malperfusion and, on a more long-term basis, elevated
pressure in the false lumen with increased aortic growth and risk for aortic
rupture. The authors sought to determine whether the number of entry
tears detected between the true and false lumen might help predict which
patients with acute type B aortic dissection are at increased risk for late aortic
dilation. The authors evaluated acute type B aortic dissection patients with
uncomplicated dissection. Patients with a CTA obtained at clinical presen-
tation and another CTA at least 90 days after medical treatment were
included from the years 2005 to 2010. Aortic diameters were measured
at ﬁve levels on the base line CTA and on last available CTA with annual
aortic growth rates calculated. The number of entry tears between the
true and false lumen were also determined. Number of entry tears and
the location of entry tears in the aorta were then compared with aortic
growth rates. There were 60 patients with 243 dissected segments. Mean
growth rates during follow-up (median, 23.2 months, range, 3-132
months) were higher in patients with one entry tear (5.6 6 8.9 mm) than
those with two (2.1 6 1.7 mm; P ¼ .001) and three entry tears (mean,
2.2 6 4.1; P ¼ .010). Distance of the primary entry tear from the left sub-
clavian artery did not have an effect on aortic growth rate (median, 38 mm;
interquartile range, 24-137 mm; P ¼ .434).
Comment: The data are somewhat limited by the fact that in the clin-
ical setting, imaging of acute aortic dissections may vary with respect to the
cardiac cycle, conﬁguration of the aortic lumen, and changes of the ﬂap dur-
ing systole and diastole. Dynamic CT scanning rather than static scanning
used in this study may have also identiﬁed additional entry tears. The aortic
dissection process is complex and in some respects the data may argue for
more routine use of dynamic CT imaging in patients with acute type B
aortic dissection. It is only through improved understanding of the dissec-
tion process that better selection of patients with acute type B aortic dissec-
tion for immediate intervention will be determined.
Flow Reversal Versus Filter Protection: A Pilot Carotid Artery
Stenting Randomized Trial
de Castro-Afonso LH, Abud LG, Rolo JG, et al. Circ Cardiovasc Interv
2013;6:552-9.
Conclusions: During carotid artery stenting (CAS) using a femoral
approach, ﬁlter protection is more effective than ﬂow reversal in reducing
ischemic brain lesions.
Summary: Embolic protection devices (EPDs) have been associated
with improved clinical outcomes in CAS (Kastrup A et al, Stroke
2003;34:813-9; and Garg N et al, J Endovasc Ther 2009;16:412-27).
The most widely used EPDs are distal protective techniques using ﬁlter de-
vices. An alternative strategy to protect the brain during CAS procedures is
to use proximal protective techniques. With proximal protection, common
and external carotid arteries are occluded promoting ﬂow arrest or ﬂow
reversal of the target internal carotid artery. Theoretically, this establishes
brain protection to cross and treat the carotid stenosis during CAS. This pi-
lot trial was designed to compare ﬂow reversal vs ﬁlter protection during
CAS using femoral access techniques. The trial was a randomized,prospective, open-label (blinded outcomes), single-center, superiority trial.
Patients undergoing CAS were randomly enrolled to have either ﬂow
reversal or ﬁlter protection during the procedure. The primary end points
of the study were the incidence, number, and size of new ischemic brain le-
sions after CAS. Secondary end points included major adverse cardiac and
cerebrovascular events, transient ischemic attack, and deﬁnitive ischemic
brain lesions on ﬂuid-attenuated inversion recovery magnetic resonance im-
aging at the 3-month follow-up. 3T magnetic resonance imaging was used
to assess ischemic brain lesions. Neurologic outcomes were evaluated using
the modiﬁed Rankin Scale and the National Institutes of Health Stroke
Scale. There were 40 consecutive patients randomly assigned in the study.
Compared with ﬂow reversal (n ¼ 21), ﬁlter protection (n ¼ 19) resulted
in a signiﬁcant reduction in the incidence (15.8% vs 47.6%; P ¼ .03), num-
ber (0.73 vs 2.6; P ¼ .05), and size (0.81 vs 2.23 mm; P ¼ .05) of new
ischemic brain lesions. One patient in each group presented with a transient
ischemic attack at the 3-month follow-up. No major adverse cardiac or
cerebrovascular events occurred in the hospital or at the 3-month follow-
up period.
Comment: One potential criticism of the study will be the learning
curve effect. The primary operator for the trial apparently has performed
450 CAS procedures, of which 412 cases used ﬁlter devices and only 27
cases used proximal protection devices with ﬂow arrest and 12 cases with
proximal protection and ﬂow reversal prior to randomization in the trial.
This was also a single-institution study. However, the authors did have pre-
cise and speciﬁc predetermined end points for their study and the trial did
demonstrate ﬁlter protection was more effective than ﬂow reversal in
reducing ischemic brain lesions during CAS. The results are what they
are, but obviously larger trials will be necessary to conﬁrm the author’s ﬁnd-
ings and the clinical implications of these ﬁndings.
Management and Outcomes of Major Bleeding During Treatment
With Dabigatran or Warfarin
Majeed A, Hwang H-G, Connolly SJ, et al. Circulation 2013;124:2325-32.
Conclusions: Patients experiencing major bleeding on dabigatran
require more red cell transfusions, less plasma, shorter intensive care unit
stays, and have a trend to lower mortality compared to those with major
bleeding on warfarin.
Summary: Dabigatran is approved in more than 80 countries in the
world for stroke prevention in patients with atrial ﬁbrillation. There is supe-
rior stroke reduction with dabigatran 150-mg twice daily and noninferior
stroke prevention with dabigatran 110 mg twice daily compared with
warfarin with a target international normalized ratio of 2 to 3 (Connolly
SJ et al, N Engl J Med 2009;361:1139-51). With respect to bleeding, major
bleeding in patients treated with dabigatran 150-mg twice daily is similar to
that in patients treated with warfarin. In patients treated with dabigatran
110-mg twice daily, major bleeding is less than in patients treated with
warfarin. In patients with venous thromboembolism, there is also a lower
rate of bleeding with dabigatran 150-mg twice daily compared with warfarin
with a target international normalized ratio of 2.0 to 3.0 (Schulman S et al,
N Engl J Med 2009;361:2342-52). Warfarin has a half-life of 36 to 48
hours, but it’s anticoagulant effect can be reversed within 10 to 20 minutes
by prothrombin complex concentrates and within 6 to 12 hours by vitamin
K (Holbrook A et al, Chest 2012;141(2 Suppl):e152S-84S). Dabigatran
does not have an antidote and has a half-life of 12 to 14 hours (Stangier
J et al, Br J Clin Pharmacol 2007;64:292-303). In patients with life-threat-
ening bleeding on dabigatran, hemodialysis might help restore hemostasis in
combination with activated charcoal to prevent gastrointestinal absorption
of recently ingested drug, as well as administration of prothrombin concen-
trates or recombinant factor VII. Evidence as to the efﬁcacy of reversal
of dabigatran, however, is limited primarily to experimental and animal
studies and isolated case reports. The objective of the study presented
here was to describe management of major bleeding and outcomes after
bleeding in large phase III trials evaluating the efﬁcacy and safety of long-
term dabigatran ($6 months) compared with warfarin. Two independent
investigators reviewed bleeding reports from 1034 individuals with 1121871
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warfarin in 27,419 patients treated for 6 to 36 months. There were 627
of 16,755 patients on dabigatran who had major bleeds. These patients
were older, had lower creatinine clearances, and more frequently used
aspirin or nonsteroid anti-inﬂammatory agents than those on warfarin
with major bleeds (n ¼ 407 of 10,002). Thirty-day mortality after the ﬁrst
major bleed tended to be lower in the dabigatran group (9.1%) than in the
warfarin group (13.0%; pooled odds ratio, 0.68; 95% conﬁdence interval,
0.46-1.01; P ¼ .057). With adjustments for sex, age, weight, renal function
and concomitant antithrombotic therapy, the pooled odds ratio for 30-day
mortality with dabigatran vs warfarin was 0.66 (95% conﬁdence interval,
0.144-1.00; P ¼ .051). In dabigatran patients with major bleeds, the
bleeding was more frequently treated with blood transfusions (61%) than
bleeds in warfarin patients (42%; P < .001). Patients with major bleeds
treated with dabigatran were less frequently treated with plasma compared
to warfarin patients with major bleeds (19.8% vs 30.2%; P < .001). Patients
with major bleeds had shorter stays in intensive care units if they had previ-
ously received dabigatran (mean,1.6 nights) compared with those who had
received warfarin (mean, 2.7 nights; P ¼ .01).
Comment: There is obviously no ideal anticoagulant agent. Despite
the fact there is no reversal agent for dabigatran, outcomes of major
bleeding on this drug appear no worse and are perhaps slightly better
than outcomes for patients with major bleeding on warfarin. It does not
appear overall resources needed to manage major bleeding on dabigatran
are greater than to manage such bleeding on warfarin. It also does not
appear that the prognosis after major bleeding is worse with dabigatran
than with warfarin despite the lack of a reversal agent for dabigatran. Dabi-
gatran is an alternative to warfarin with similar or superior efﬁcacy and over-
all lower risk of major bleeding. Bleeding episodes can be managed
satisfactorily with relatively simple measures such as drug discontinuation
and transfusion of red cells. Thus, the overall safety proﬁle of dabigatran
compared to warfarin remains favorable. Nevertheless, it is still desirable
to develop a speciﬁc antidote to dabigatran.
Effect of Smoking on Comparative Efﬁcacy of Antiplatelet Agents:
Systematic Review, Meta-Analysis, and Indirect Comparison
Gagne JJ, Bykov K, Choudhry NK, et al. BMJ 2013;347:f5307.
Conclusions: In randomized clinical trials of antiplatelet drugs, the
reported clinical beneﬁt of clopidogrel to reduce cardiovascular death,
myocardial infarction, and stroke is seen primarily in patients who smoke,
with little demonstrated beneﬁt in nonsmokers.
Summary: Recent subgroup analyses of randomized controlled trials
evaluating clopidogrel in cardiovascular disease have raised the question if
the efﬁcacy of the drug occurs primarily or exclusively among smokers
(Grubel PA et al, JAMA 2012;307:2495-6). Biochemically clopidogrel is
a prodrug. It requires a two-step metabolic activation process to attain
active form. Smoking induces cytochrome P450 isoenzyme 1 A2. This is
a key enzyme involved in the ﬁrst activation step of clopidogrel. It has
therefore been postulated that smoking increases the availability of clopi-
dogrel’s active metabolite, thereby enhancing its efﬁcacy. There are also
numerous antiplatelet agents such as prasugrel, also a prodrug but
requiring a less complex activation process than clopidogrel. Another
new antiplatelet agent, ticagrelor, is active by itself. In this paper, the au-
thors performed a systematic review, meta-analysis, and indirect compari-
sons to quantify the efﬁcacy of clopidogrel separately in smokers and
nonsmokers. They also sought to compare the efﬁcacy of newer antiplatelet
agents in these groups of patients. Data sources included Medline (1966-
present) and Embase (1974-present), along with supplementary searches
of databases of abstracts from major cardiology conferences. Also used
were the Index to Nursing and Allied Health (CINAHL), the CAB Ab-
stracts databases, and Google Scholar. Randomized trials of clopidogrel,
prasugrel, or ticagrelor that also examined clinical outcomes among sub-
groups of smokers and nonsmokers were identiﬁed. Two of the current au-
thors independently extracted all data, including information on patient
populations included in the trials, treatment types and doses, deﬁnitions
of clinical outcomes and duration of follow-up, deﬁnitions of smoking sub-
groups and number of patients in each group, and effect estimates with
95% conﬁdence intervals for each smoking status subgroup. There were
nine eligible randomized trials. One investigated clopidogrel compared
with aspirin, four investigated clopidogrel plus aspirin compared with
aspirin alone, and one investigated double dose clopidogrel compared
with standard dose clopidogrel. These trials included 74,489 patients of
whom 21,717 (29%) were smokers. Among smokers, those randomized
to clopidogrel, experienced a 25% reduction in the primary composite clin-
ical outcome of cardiovascular death, myocardial infarction, and stroke
compared with patients in the control group (relative risk [RR], 0.75;95% conﬁdence interval [CI], 0.67-0.83). There was just an 8% decrease
in nonsmokers in the composite outcome (RR, 0.92; 95% CI, 0.87-
0.98). There were two studies that investigated prasugrel plus aspirin
compared with clopidogrel plus aspirin, and one study investigated ticagre-
lor plus aspirin compared with clopidogrel plus aspirin. In smokers, the RR
was 0.71 (95% CI, 0.61-0.82) for prasugrel compared with clopidogrel and
0.83 (95% CI, 0.68-1.00) for ticagrelor compared with clopidogrel. Cor-
responding RRs among nonsmokers were 0.92 (95% CI, 0.83-1.01) and
0.89 (95% CI, 0.79-1.00).
Comment: The data suggest that clinicians may consider potential
beneﬁts and risks of antiplatelet drugs differently for those patients that
continue to smoke and those that do not. However, there is little under-
standing, or no understanding, of how the potential enhanced antiplatelet
effect in smokers might also increase the risk of bleeding. It will be impor-
tant to design future trials to determine whether different doses of clopidog-
rel should be used in smokers and nonsmokers to achieve clinical beneﬁt.
Electronic Cigarettes for Smoking Cessation: A Randomised
Controlled Trial
Bullen C, Howe C, Laugesen M, et al. Lancet 2013;382:1629-37.
Conclusions: Electronic cigarettes are associated with few adverse
events and, with or without nicotine, are modestly effective in aiding smok-
ing cessation. Results are similar to achievement of abstinence with nicotine
patches.
Summary: Electronic cigarettes were ﬁrst introduced in 2004. These
devices span a range of individual devices, many of which vaporize nicotine
for inhalation. Twenty-seven precent of patients making an attempt to quit
cigarettes in the UK have utilized electronic cigarettes (West R, July 20,
2012; http://www.smokinginengland.info/lastest-statistics/; accessed
August 9, 2013). It has been predicted that sales are increasing so rapidly
they will surpass actual cigarette sales within the decade (Purkayastha D;
http://www.thefreelibrary.com/;BAT Ramps-up E-cigarette Expansion
as Sales Go Up in Smoke). One trial, however, of 300 smokers demon-
strated low rates of cessation at 12 months for both nicotine e-cigarettes
and placebo e-cigarettes (Caponnetto P et al, PloS One 2013;8:e66317).
There is also controversy as to whether electronic cigarettes have the poten-
tial to produce harm (U.S. Food and Drug Administration; http://www.
fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm). This trial
sought to access whether electronic cigarettes with cartridges containing
nicotine were more effective for smoking cessation than nicotine patches.
There was also a blind comparison with electronic cigarettes containing
no nicotine (placebo e-cigarette). The hypothesis was that nicotine e-ciga-
rettes would be a more effective than patches and placebo e-cigarettes for
smoking reduction, tobacco dependence, and relief of withdrawal symptoms
and that there would be no greater risk of adverse events than with nicotine
patches. This was a randomized, controlled superiority trial from Aukland,
New Zealand conducted between September 6, 2011 and July 5, 2013.
Adult smokers ($18 years) wanting to quit were randomized and stratiﬁed
by ethnicity, sex, and level of nicotine dependence in a 4:4:1 ratio of 16-mg
nicotine e-cigarettes, nicotine patches (21 mg patch, one daily), or placebo
e-cigarettes (no nicotine), from 1 week before until 12 weeks after quit day.
There was also additional low intensity behavioral support via voluntary tele-
phone counseling. Primary outcome was biochemically veriﬁed continuous
abstinence at 6 months (exhaled breath carbon monoxide measurement
<10 ppm). Primary analysis was on an intention-to-treat basis. There
were 657 people randomized (289 to nicotine e-cigarettes, 295 to patches,
and 73 to placebo e-cigarettes) and who were included in the intention-to-
treat analysis. At 6 months, veriﬁed abstinence was 7.3% (21 of 289) with
nicotine e-cigarettes, 5.8 % (17 of 295) with patches, and 4.1% (3 of 73)
with placebo e-cigarettes. The risk difference for nicotine e-cigarettes vs
patches was 1.51 (95% conﬁdence interval, 2.49 to 5.51). Risk difference
for nicotine e-cigarettes vs placebo e-cigarettes was 3.16 (95% conﬁdence
interval, 2.29 to 8.61). Abstinence was substantially lower than anticipated
by prestudy power calculations.
Comment: Electronic cigarettes are big business. The study, howev-
er, would not suggest anything more than a very modest effect on absti-
nence rates through the use of electronic cigarettes. The authors found
that electronic cigarettes had higher acceptance rates among smokers
than other forms of nicotine replacement therapy. Since there were no dra-
matic differences in adverse events between other forms of nicotine
replacement therapy and electronic cigarettes, it may be possible, through
the design of more adequately powered trials, to demonstrate that elec-
tronic cigarettes can indeed have some potential for improving population
health. Currently, however, the data would not appear to support wide-
spread use of these devices if the goal is to have a signiﬁcant effect on
smoking cessation.
